Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Antisense Therapeutics Limited says US patent allowance extends strong IP position


Sunday, 6 Apr 2014 06:00pm EDT 

Antisense Therapeutics Limited:Announced that the US Patent Office has allowed US Patent 61/132973 entitled Methods for treating multiple sclerosis (MS) using antisense oligonucleotides.This covers the use of the ATL1102 compound to reduce brain lesions in relapsing-remitting multiple sclerosis (RRMS), and progressive forms of MS including secondary progressive MS (SPMS).And primary progressive MS (PPMS) and at the desired doses, until June 23, 2029, with potential for an extension of up to five years.The new US patent forms part of the Company‚Äôs extensive portfolio of intellectual property protecting ATL1102 and its uses in MS.This includes a granted United States patent US 8,415,314, Australian Patent 2009271678 and corresponding applications in Europe, Japan and Canada, covering the use of ATL1102 in the treatment of the most common form of the disease, RRMS. 

Company Quote

0.125
0.0050 +4.17%
24 Apr 2015